Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
8 "Jin Young Kim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Pemetrexed Maintenance versus Observation in Patients with Advanced Urothelial Carcinoma Who Completed First-line Platinum-based Chemotherapy without Disease Progression (PREMIER, KCSG GU16-05)
Inkeun Park, Shinkyo Yoon, Ilhwan Kim, Kwonoh Park, Suee Lee, Bhumsuk Keam, Joo-Hwan Park, Jin Young Kim, Yoon Ji Choi, Byeong Seok Sohn, Jae Lyun Lee
Received October 16, 2024  Accepted December 26, 2024  Published online December 27, 2024  
DOI: https://doi.org/10.4143/crt.2024.1003    [Accepted]
AbstractAbstract PDF
Purpose
Platinum-based chemotherapy is the standard treatment for advanced urothelial carcinoma (aUC). Switch maintenance therapy after first-line (1L) treatment may delay disease progression. This study evaluated pemetrexed as switch maintenance therapy versus observation in aUC patients without disease progression after initial chemotherapy.
Materials and Methods
Eligible aUC patients who did not progress after 4–6 cycles of cisplatin or carboplatin-based chemotherapy were randomized 1:1 to receive maintenance pemetrexed (500 mg/m2 IV every 3 weeks, up to 16 cycles) or observation. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), response rate, and safety.
Results
The trial was closed early due to slow accrual after avelumab approval. From October 2016 to December 2022, 97 patients were randomized to pemetrexed (n=49) or observation (n=48). The median age was 69 years (range: 43–90) and 66 (range33–82), respectively, with 63% and 73% of patients being male, respectively. The median PFS was 6.0 months (95% CI, 3.4–8.5) with pemetrexed versus 2.3 months (1.8–2.7) with observation (p=0.044, HR 0.64; 95% CI, 0.41–0.99). The median OS was 18.1 months (95% CI, 6.9–29.4) for pemetrexed and 17.9 months (16.1–19.7) for observation (p=0.913, HR 1.03; 95% CI, 0.61–1.73). Common adverse events in the pemetrexed group included anemia (30%), fatigue (18%), and neutropenia (12%), primarily grade 1 or 2.
Conclusion
The PREMIER trial showed that switch maintenance pemetrexed significantly prolonged PFS in aUC patients post-1L platinum-based chemotherapy, with a favorable safety profile. Further studies on combination maintenance therapies are warranted.
  • 311 View
  • 36 Download
Close layer
Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
Jin Hyoung Kang, Jung Hye Kwon, Yun-Gyoo Lee, Keon Uk Park, Ho Jung An, Joohyuk Sohn, Young Mi Seol, Hyunwoo Lee, Hwan-Jung Yun, Jin Seok Ahn, Ji Hyun Yang, Hunho Song, Dong-Hoe Koo, Jin Young Kim, Gun Min Kim, Hwa Jung Kim
Cancer Res Treat. 2020;52(3):907-916.   Published online March 18, 2020
DOI: https://doi.org/10.4143/crt.2019.713
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to compare ramosetron (RAM), aprepitant (APR), and dexamethasone (DEX) [RAD] with palonosetron (PAL), APR, and DEX [PAD] in controlling highly-emetogenic chemotherapy (HEC)–induced nausea and vomiting.
Materials and Methods
Patients were randomly assigned (1:1) to receive RAD or PAD:RAM (0.3 mg intravenously) or PAL (0.25 mg intravenously) D1, combined with APR (125 mg orally, D1 and 80 mg orally, D2-3) and DEX (12 mg orally or intravenously, D1 and 8 mg orally, D2-4). Patients were stratified by gender, cisplatin-based chemotherapy, and administration schedule. The primary endpoint was overall complete response (CR), defined as no emesis and no rescue regimen during 5 days of HEC. Secondary endpoints were overall complete protection (CP; CR+nausea score < 25 mm) and total control (TC; CR+nausea score < 5 mm). Quality of life was assessed by Functional Living Index Emesis (FLIE) questionnaire on D0 and D6.
Results
A total of 279 patients receiving RAD (n=137) or PAD (n=142) were evaluated. Overall CR rates in RAD and PAD recipients were 81.8% and 79.6% (risk difference [RD], 2.2%; 95% confidence interval [CI], −7.1 to 11.4), respectively. Overall CP and TC rates for RAD and PAD were 56.2% and 58.5% (RD, −2.3%; 95% CI, −13.9 to 9.4) and 47.5% vs. 43.7% (RD, 3.8%; 95% CI, −7.9 to 15.5), respectively. FLIE total score ≥ 108 (no impact on daily life) was comparable between RAD and PAD (73.9% vs. 73.4%, respectively). Adverse events were similar between the two groups.
Conclusion
In all aspects of efficacy, safety and QOL, RAD is non-inferior to PAD for the control of CINV in cancer patients receiving HEC.

Citations

Citations to this article as recorded by  
  • Impact of body weight-based dosing of palonosetron and ondansetron on postoperative nausea and vomiting following laparoscopic sleeve gastrectomy: a randomized, double-blind study
    Büşra Burcu, Nadir Adnan Hacım, Ozan Caliskan, Serdar Demirgan, Talar Vartanoglu Aktokmakyan, Serhat Meric, Tomris Duymaz, Onder Karabay, Ali Solmaz
    Acta Chirurgica Belgica.2024; 124(1): 41.     CrossRef
  • 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents
    Jørn Herrstedt, L Celio, PJ Hesketh, L Zhang, R Navari, A Chan, M Saito, R Chow, M Aapro
    Supportive Care in Cancer.2024;[Epub]     CrossRef
  • 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting
    J. Herrstedt, R. Clark-Snow, C.H. Ruhlmann, A. Molassiotis, I. Olver, B.L. Rapoport, M. Aapro, K. Dennis, P.J. Hesketh, R.M. Navari, L. Schwartzberg, M.L. Affronti, M.A. Garcia-Del-Barrio, A. Chan, L. Celio, R. Chow, M. Fleury, R.J. Gralla, R. Giusti, F.
    ESMO Open.2024; 9(2): 102195.     CrossRef
  • Ramosetron 3.0 μg/mL Combining with Dexamethasone (0.05, 0.1, 0.2 mg/mL) in Infusion Solutions: A Physicochemical Stability Study
    Baoxia Fang, Lijun Zhao, Shirong Yu, Fuchao Chen
    Dose-Response.2024;[Epub]     CrossRef
  • Efficacy and safety of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis
    Marco Filetti, Pasquale Lombardi, Raffaele Giusti, Rosa Falcone, Florian Scotte, Diana Giannarelli, Antonella Carcagnì, Valeria Altamura, Giovanni Scambia, Gennaro Daniele
    Cancer Treatment Reviews.2023; : 102512.     CrossRef
  • Effect of Acupuncture on Delayed Emesis for the Patients Who Received High-Emetogenic Chemotherapy with Standard Antiemetic Prophylaxis (KHMC-HO-01): An Open-Label, Randomized Study
    Chi Hoon Maeng, Seunghoon Lee, Jae Joon Han, Hong Jun Kim, Dongwoo Nam, Junhee Lee, Sun Kyung Baek, Maria Grazia Ferraro
    Evidence-Based Complementary and Alternative Medicine.2022; 2022: 1.     CrossRef
  • Cardioprotective action of aprepitant in a rat model of ischemia-reperfusioninduced myocardial injury: role of PI3K-AkT-GSK-3β-HIF-1α signaling pathway
    Mei Qian, Yang Liu
    Acta Cirúrgica Brasileira.2022;[Epub]     CrossRef
  • Comparison of the Effectiveness of Palonosetron and Ramosetron in Preventing Postoperative Nausea and Vomiting: Updated Systematic Review and Meta-Analysis with Trial Sequential Analysis
    Hyo Jin Kim, EunJin Ahn, Geun Joo Choi, Hyun Kang
    Journal of Personalized Medicine.2022; 13(1): 82.     CrossRef
  • Oliceridine is Associated with Reduced Risk of Vomiting and Need for Rescue Antiemetics Compared to Morphine: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials
    Timothy L. Beard, Cathy Michalsky, Keith A. Candiotti, Paul Rider, Linda Wase, Ashraf S. Habib, Mark A. Demitrack, Michael J. Fossler, Eugene R. Viscusi
    Pain and Therapy.2021; 10(1): 401.     CrossRef
  • Forsythiae Fructus aqueous extract attenuates cisplatin-induced kaolin consumption (pica) by inhibiting NLRP3 inflammasome activation in rats
    Qi Meng, Pingping Bi, Guanglong Zhang, Yaqi Li, Siqi Chen, Ke Nie
    Bioscience, Biotechnology, and Biochemistry.2021; 85(9): 2054.     CrossRef
  • Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis
    Vanessa Piechotta, Anne Adams, Madhuri Haque, Benjamin Scheckel, Nina Kreuzberger, Ina Monsef, Karin Jordan, Kathrin Kuhr, Nicole Skoetz
    Cochrane Database of Systematic Reviews.2021;[Epub]     CrossRef
  • Duration of dexamethasone administration for the prevention of chemotherapy-induced nausea and vomiting – A systematic review and meta-analysis
    Ajay Raghunath, Sahan D. Chandrasekara, Shane N. Anthony, Ben Markman
    Critical Reviews in Oncology/Hematology.2020; 152: 103012.     CrossRef
  • 9,815 View
  • 199 Download
  • 10 Web of Science
  • 12 Crossref
Close layer
Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea
Hee Yeon Lee, Ji Hyung Hong, Jae Ho Byun, Hee-Jun Kim, Sun Kyung Baek, Jin Young Kim, Ki Hyang Kim, Jina Yun, Jung A Kim, Kwonoh Park, Hyo Jin Lee, Jung Lim Lee, Young-Woong Won, Il Hwan Kim, Woo Kyun Bae, Kyong Hwa Park, Der-Sheng Sun, Suee Lee, Min-Young Lee, Guk Jin Lee, Sook Hee Hong, Yun Hwa Jung, Ho Jung An
Cancer Res Treat. 2020;52(1):277-283.   Published online July 12, 2019
DOI: https://doi.org/10.4143/crt.2019.292
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to evaluate clinical characteristics and treatment pattern of ovarian clear cell carcinoma (OCCC) in Korea and the role of adjuvant chemotherapy in early stage.
Materials and Methods
Medical records of 308 cases of from 21 institutions were reviewed and data including age, performance status, endometriosis, thromboembolism, stage, cancer antigen 125, treatment, recurrence, and death were collected.
Results
Regarding stage of OCCC, it was stage I in 194 (63.6%), stage II in 34 (11.1%), stage III in 66 (21.6%), and stage IV in 11 (3.6%) patients. All patients underwent surgery. Optimal surgery (residual disease ≤ 1 cm) was achieved in 89.3%. Majority of patients (80.5%) received postoperative chemotherapy. The most common regimen was taxane-platinum combination (96%). Median relapse-free survival (RFS) was 138.5 months for stage I, 33.4 for stage II, 19.3 for stage III, and 9.7 for stage IV. Median overall survival (OS) were not reached, 112.4, 48.7, and 18.3 months for stage I, II, III, and IV, respectively. Early-stage (stage I), endometriosis, and optimal debulking were identified as favorable prognostic factors for RFS. Early-stage and optimal debulking were also favorable prognostic factors for OS. Majority of patients with early-stage received adjuvant chemotherapy. However, additional survival benefit was not found in terms of recurrence.
Conclusion
Majority of patients had early-stage and received postoperative chemotherapy regardless of stage. Early-stage and optimal debulking were identified as favorable prognostic factors. In stage IA or IB, adding adjuvant chemotherapy did not show difference in survival. Further study focusing on OCCC is required.

Citations

Citations to this article as recorded by  
  • Ovarian clear cell carcinoma: open questions on the management and treatment algorithm
    Roberta Rosso, Margherita Turinetto, Fulvio Borella, Nicolas Chopin, Pierre Meeus, Alexandra Lainè, Isabelle Ray-Coquard, Olivia Le Saux, Domenico Ferraioli
    The Oncologist.2025;[Epub]     CrossRef
  • From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer
    Zesi Liu, Chunli Jing, Fandou Kong
    Journal of Ovarian Research.2024;[Epub]     CrossRef
  • SOX17 expression in ovarian clear cell carcinoma
    Daichi Kodama, Motoki Takenaka, Chiemi Saigo, Masako Azuma, Yuki Hanamatsu, Masanori Isobe, Tamotsu Takeuchi
    Journal of Ovarian Research.2024;[Epub]     CrossRef
  • Construction of a Prediction Model of Cancer-Specific Survival after Ovarian Clear Cell Carcinoma Surgery
    Mengqi Huang, Li Ling, Yanbo Liu, Yujuan Li
    Clinical and Experimental Obstetrics & Gynecology.2024;[Epub]     CrossRef
  • Patients with stage IA ovarian clear cell carcinoma do not require chemotherapy following surgery
    Li Shuqing, Zhu Zhiling
    Cancer Medicine.2023; 12(6): 6668.     CrossRef
  • Clear cell carcinoma of the ovary and venous thromboembolism: a systematic review and meta-analysis
    Hamidreza Didar, Farah Farzaneh, Hanieh Najafiarab, Kosar Namakin, Kimiya Gohari, Ali Sheidaei, Sepehr Ramezani
    Current Medical Research and Opinion.2023; 39(6): 901.     CrossRef
  • The Significance of Radiotherapy in Ovarian Clear Cell Carcinoma: A Systematic Review and Meta-Analysis
    Yuan Zhuang, Hua Yang
    Cancer Control.2023;[Epub]     CrossRef
  • Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer
    Satoe Fujiwara
    Japanese Journal of Clinical Oncology.2023; 53(8): 664.     CrossRef
  • Application of precision medicine based on next-generation sequencing and immunohistochemistry in ovarian cancer: a real-world experience
    Yoo-Na Kim, Yun Soo Chung, Ji Hyun Lee, Eunhyang Park, Seung-Tae Lee, Sunghoon Kim, Jung-Yun Lee
    Journal of Gynecologic Oncology.2023;[Epub]     CrossRef
  • Characteristics and Prognosis of Ovarian Pure Clear Cell Carcinoma: A Retrospective Experience of 136 Patients
    Yang Gao, Wei Ding, Pengpeng Qu
    Clinical and Experimental Obstetrics & Gynecology.2023;[Epub]     CrossRef
  • A clearer view on ovarian clear cell carcinoma
    Aglaja De Pauw, Eline Naert, Koen Van de Vijver, Tummers Philippe, Katrien Vandecasteele, Hannelore Denys
    Acta Clinica Belgica.2022; 77(4): 792.     CrossRef
  • Friend or foe? The prognostic role of endometriosis in women with clear cell ovarian carcinoma. A UK population-based cohort study
    Anastasios Tranoulis, Felicia Helena Buruiana, Bindiya Gupta, Audrey Kwong, Aarti Lakhiani, Jason Yap, Janos Balega, Kavita Singh
    Archives of Gynecology and Obstetrics.2022; 305(5): 1279.     CrossRef
  • Association Between Endometriosis and Prognosis of Ovarian Cancer: An Updated Meta-Analysis
    Peng Chen, Chi-Yuan Zhang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report
    Abdulkarim Mohamed Farah, Shiyu Gu, Yan Jia
    Medicine.2022; 101(37): e30666.     CrossRef
  • Clear cell carcinoma of the ovary: a clinical and molecular perspective
    Yasushi Iida, Aikou Okamoto, Robert L Hollis, Charlie Gourley, C Simon Herrington
    International Journal of Gynecological Cancer.2021; 31(4): 605.     CrossRef
  • Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study
    Chenchen Zhu, Jing Zhu, Lili Qian, Hanyuan Liu, Zhen Shen, Dabao Wu, Weidong Zhao, Weihua Xiao, Ying Zhou
    BMC Cancer.2021;[Epub]     CrossRef
  • The oncological outcome of the patients with ovarian clear cell cancer: Platinum-based adjuvant chemotherapy is not suitable
    Caner ÇAKIR, Fatih KILIÇ, Çiğdem KILIÇ, Dilek YÜKSEL, Vakkas KORKMAZ, Günsu KİMYON CÖMERT, Osman TÜRKMEN, Taner TURAN
    Journal of Surgery and Medicine.2021; 5(8): 1.     CrossRef
  • Development and validation of Nomograms for predicting overall survival and Cancer-specific survival in patients with ovarian clear cell carcinoma
    Qian Chen, Shu Wang, Jing-He Lang
    Journal of Ovarian Research.2020;[Epub]     CrossRef
  • 8,989 View
  • 421 Download
  • 22 Web of Science
  • 18 Crossref
Close layer
Special Article
Behaviors and Attitudes toward the Use of Complementary and Alternative Medicine among Korean Cancer Patients
Jung Hye Kwon, Sang-Cheol Lee, Myung Ah Lee, Yu Jung Kim, Jung Hun Kang, Jin Young Kim, Hyo Jin Lee, Woo Kyun Bae, Mi-Jung Kim, Eui Kyu Chie, Jin Kim, Yeul Hong Kim, Hyun Cheol Chung, Sun Young Rha
Cancer Res Treat. 2019;51(3):851-860.   Published online June 7, 2019
DOI: https://doi.org/10.4143/crt.2019.137
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
A cross-sectional survey was conducted to explore the current awareness and use of complementary and alternative medicine (CAM), as well as attitudes toward CAM, in patients with cancer and their family members in South Korea.
Materials and Methods
Between September 21 and October 31, 2017, a 25-item questionnaire regarding CAM experiences among cancer patients and their family members was conducted in 10 oncology clinics in South Korea after institutional review board approval at each institution.
Results
In total, 283/310 patients were analyzed. The median age was 60 years, and 60% were male. Most of the patients were actively receiving anticancer treatment at the time of the survey. A total of 106 patients (37%) had experienced a median of two types (interquartile range, 1 to 3) of CAM. Belief in CAM (odds ratio [OR], 3.015; 95% confidence interval [CI], 1.611 to 5.640) and duration of disease (OR, 1.012; 95% CI, 1.004 to 1.020) were independent factors for using CAM in multivariable analysis. Belief in CAM was significantly associated with current use of CAM (OR, 3.633; 95% CI, 1.567 to 8.424). Lay referral was the most common reason for deciding to use CAM, and only 25% of patients (72/283) discussed CAM with their physicians.
Conclusion
Patient attitudes toward and confidence in CAM modalities were strongly associated with their CAM experiences, and only a small number of patients had an open discussion about CAM with their physicians. A patient education program for CAM is needed.

Citations

Citations to this article as recorded by  
  • Bridging the gap: attitudes and practices toward complementary and alternative medicine among oncology patients and healthcare professionals in Croatia
    Ljerka Armano, Vanja Vasiljev, Tomislav Rukavina, Denis Juraga, Aleksandar Racz, Vanja Tešić
    Frontiers in Psychology.2025;[Epub]     CrossRef
  • The Relationship Between Cancer Patients’ Supportive Care Needs and Their Attitudes Toward Complementary and Alternative Medicine
    H Çelik, H Aslan
    Nigerian Journal of Clinical Practice.2024; 27(4): 415.     CrossRef
  • Complementary and alternative medicine use and its impact on quality of life among cancer patients in Freetown, Sierra Leone: considerations for a resource-limited setting
    Onome T. Abiri, Matilda Seinya Sheriff, Isaac O. Smalle, Nellie V.T. Bell, Ibrahim Franklyn Kamara, Thaim B. Kamara, Constance Cummings-John, Joshua Coker, Abdulai Jawo Bah, Joseph Sam Kanu, Ronita Luke, Lannes Kamara, John Smith, Mohamed Samai
    Discover Medicine.2024;[Epub]     CrossRef
  • Cancer care beyond the conventional: Challenges of integrative oncology in India
    Parvathy Venate, Vitthal G. Huddar
    Ayush Journal of Integrative Oncology.2024; 1(3 & 4): 35.     CrossRef
  • Alternative and complementary medicine in neurological disorders and neurological disability patients: Prevalence, factors, opinions and reasons
    Paul Carrillo-Mora, Marlene A. Rodríguez-Barragán, Jimena Quinzaños-Fresnedo, María del Refugio Pacheco-Gallegos, María Soto-Lara, Monserrat Velázquez-Ortega, María Fernanda Villarreal-Azamar, Ilse Jocelyn Aguirre-Medina, Mariana Rubalcava-Gracia-Medrano
    Complementary Therapies in Medicine.2023; 72: 102920.     CrossRef
  • Status of Using Complementary and Alternative Medicine among Patients with Cancer in Korea: an Online Survey of Online Cancer Support Groups (KCSG PC21-20)
    Jung Sun Kim, Jung Hye Kwon, Sun Young Rha, Sang-Cheol Lee, Yoon Jung Chang, In-Sun Kwon, Kyung Han You, Ho Young Yoon
    Cancer Research and Treatment.2023; 55(2): 442.     CrossRef
  • Effects of COVID-19 fear and anxiety on attitudes towards complementary and alternative medicine use in women with gynecological cancer during the COVID-19 pandemic
    Fatma Uslu-Sahan, Ilknur Yesilcınar, Gonul Kurt, Elif Hancer, Gulten Guvenc
    Journal of Integrative Medicine.2023; 21(4): 377.     CrossRef
  • Use of Complementary and Alternative Medicine for Prostate Cancer among African Americans, African Immigrants and Caribbean Immigrants
    Nipher Malika, Lisa Roberts, Carlos Casiano, Susanne Montgomery
    Journal of Community Health.2022; 47(2): 284.     CrossRef
  • Traditional and complementary medicine use among cancer patients in Nepal: a cross-sectional survey
    Soo Jeung Choi, Sangita Karki Kunwor, Hyea Bin Im, Jung Hye Hwang, Dain Choi, Dongwoon Han
    BMC Complementary Medicine and Therapies.2022;[Epub]     CrossRef
  • The effect of cancer on traditional, complementary and alternative medicine utilization in Korea: a fixed effect analysis using Korea Health Panel data
    Dongsu Kim, Soo-Hyun Sung, Seungwon Shin, Minjung Park
    BMC Complementary Medicine and Therapies.2022;[Epub]     CrossRef
  • Use of Complementary and Alternative Medicine (CAM) in Patients With Colorectal Cancer
    Jeongwon Yeom, Jung Mi Lee
    Clinical Nutrition Research.2022; 11(4): 255.     CrossRef
  • Cancer Research Trends in Traditional Korean Medical Journals since 2000 - Topic Modeling Using Latent Dirichlet Allocation and Keyword Network Analysis
    Kyeore Bae
    The Journal of Internal Korean Medicine.2022; 43(6): 1075.     CrossRef
  • Borders between integrative medicine and EBM: significance, potential for use and legal issues in European Union member states. Narrative review
    Aneta Brygida Jędrzejewska, Barbara Janina Ślusarska, Grzegorz Józef Nowicki
    Pielegniarstwo XXI wieku / Nursing in the 21st Century.2022; 21(2): 122.     CrossRef
  • Evaluation of outpatient cancer patients’ use of nonpharmacological methods in the management of chemotherapy-induced nausea and vomiting
    Eda ERGİN, Tülay SAĞKAL MİDİLLİ, Eda AKDAĞ, Ceyda KIRGÖZ
    Cukurova Medical Journal.2021; 46(2): 574.     CrossRef
  • The Current Status of Integrative Oncology in Korea
    Eun-Bin Kwag, Soo-Dam Kim, Ji Hye Park, So-Jung Park, Mi-Kyung Jeong, Hwa-Seung Yoo
    Integrative Cancer Therapies.2021;[Epub]     CrossRef
  • Biologically-Based Complementary and Alternative Medicine (CAM) Use in Cancer Patients: The Good, the Bad, the Misunderstood
    Kathryn Knecht, David Kinder, Amy Stockert
    Frontiers in Nutrition.2020;[Epub]     CrossRef
  • Efficacy of Chemotherapy Integrated With Traditional Korean Medicine in Patients With Metastatic Pancreatic Cancer: A Single-Center Retrospective Study
    Eun Hye Kim, Jee-Hyun Yoon, Sung Soo Yoon, Jee Young Lee, Seong Woo Yoon
    Integrative Cancer Therapies.2020;[Epub]     CrossRef
  • 9,379 View
  • 225 Download
  • 15 Web of Science
  • 17 Crossref
Close layer
Original Articles
Prospective Validation of The Korean Cancer Study Group Geriatric Score (KG)-7, a Novel Geriatric Screening Tool, in Older Patients with Advanced Cancer Undergoing First-line Palliative Chemotherapy
Jin Won Kim, Se Hyun Kim, Yun-Gyoo Lee, In Gyu Hwang, Jin Young Kim, Su-Jin Koh, Yoon Ho Ko, Seong Hoon Shin, In Sook Woo, Soojung Hong, Tae-Yong Kim, Ji Yeon Baek, Hyun Jung Kim, Hyo Jung Kim, Myung Ah Lee, Jung Hye Kwon, Yong Sang Hong, Hun-Mo Ryoo, Kyung Hee Lee, Jee Hyun Kim
Cancer Res Treat. 2019;51(3):1249-1256.   Published online January 2, 2019
DOI: https://doi.org/10.4143/crt.2018.451
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to prospectively validate the Korean Cancer Study Group Geriatric Score (KG)-7, a novel geriatric screening tool, in older patients with advanced cancer planned to undergo first-line palliative chemotherapy.
Materials and Methods
Participants answered the KG-7 questionnaire before undergoing geriatric assessment (GA) and first-line palliative chemotherapy. The performance of KG-7 was evaluated by calculating the sensitivity (SE), specificity (SP), positive and negative predictive value (PPV and NPV), balanced accuracy (BA), and area under the curve (AUC).
Results
The baseline GA and KG-7 results were collected from 301 patients. The median age was 75 years (range, 70 to 93 years). Abnormal GA was documented in 222 patients (73.8%). Based on the ≤ 5 cut-off value of KG-7 for abnormal GA, abnormal KG-7 score was shown in 200 patients (66.4%). KG-7 showed SE, SP, PPV, NPV, and BA of 75.7%, 59.7%, 84.4%, 46.0%, and 67.7%, respectively; AUC was 0.745 (95% confidence interval, 0.687 to 0.803). Furthermore, patients with higher KG-7 scores showed significantly longer survival (p=0.006).
Conclusion
KG-7 appears to be adequate in identifying patients with abnormal GA prospectively. Hence, KG-7 can be a useful screening tool for Asian countries with limited resources and high patient volume.

Citations

Citations to this article as recorded by  
  • Comparison of two frailty screening tools in older patients with colorectal cancer
    Han Zhao, Xinlin Lu, Senshuang Zheng, Danmei Wei, Lizhong Zhao, Yuan Wang, Geertruida H. de Bock, Wenli Lu
    BMC Geriatrics.2023;[Epub]     CrossRef
  • Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study
    In Gyu Hwang, Minsuk Kwon, Jin Won Kim, Se Hyun Kim, Yun-Gyoo Lee, Jin Young Kim, Su-Jin Koh, Yoon Ho Ko, Seong Hoon Shin, Soojung Hong, Tae-Yong Kim, Sun Young Kim, Hyun Jung Kim, Hyo Jung Kim, Myung Ah Lee, Jung Hye Kwon, Yong Sang Hong, Kyung Hee Lee,
    Cancers.2021; 13(2): 331.     CrossRef
  • A single-arm feasibility study of gradual dose de-escalation of antiemetic dexamethasone for older patients receiving chemotherapy
    Koung Jin Suh, Seonghae Yoon, Jin Won Kim, Seo Hyun Yoon, Ji-Won Kim, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jong Seok Lee, Jee Hyun Kim
    Journal of Geriatric Oncology.2021; 12(6): 922.     CrossRef
  • Predictive Value of Geriatric Oncology Screening and Geriatric Assessment in Older Patients with Solid Cancers: Protocol for a Danish prospective cohort study (PROGNOSIS-G8)
    Helena Møgelbjerg Ditzel, Ann-Kristine Weber Giger, Cecilia Margareta Lund, Henrik Jørn Ditzel, Afsaneh Mohammadnejad, Per Pfeiffer, Jesper Ryg, Trine Lembrecht Jørgensen, Marianne Ewertz
    Journal of Geriatric Oncology.2021; 12(8): 1270.     CrossRef
  • The Globalization of Geriatric Oncology: From Data to Practice
    Ravindran Kanesvaran, Supriya Mohile, Enrique Soto-Perez-de-Celis, Harpreet Singh
    American Society of Clinical Oncology Educational Book.2020; (40): e107.     CrossRef
  • 9,520 View
  • 180 Download
  • 4 Web of Science
  • 5 Crossref
Close layer
Metachronous Double Primary Cancer after Treatment of Breast Cancer
Jin Young Kim, Hong Suk Song
Cancer Res Treat. 2015;47(1):64-71.   Published online October 27, 2014
DOI: https://doi.org/10.4143/crt.2013.215
AbstractAbstract PDFPubReaderePub
Purpose
The pattern of double primary cancer after treatment for breast cancer is important for patient survival.
Materials and Methods
We analyzed 108 cases of metachronous double primary cancer in breast cancer patients treated from 1999 to 2012.
Results
Metachronous double primary cancers occurred in 108 of 2,657 patients (4.1%) with breast cancer. The median time to the occurrence of second cancer after diagnosis of the first was 58.4±41.2 months (range, 6.9 to 180.2 months). The most common cancer was thyroid cancer, which occurred in 45 patients (41.7%). This was followed by gastric cancer in 16 patients (14.8%), endometrial cancer in 10 patients (9.3%), and cervical cancer in seven patients (6.5%). The relative risk showed a significant increase in endometrial (4.78; 95% confidence interval [CI], 1.66 to 13.79), gastric (2.61; 95% CI, 1.68 to 4.06), and thyroid cancer (1.95; 95% CI, 1.37 to 2.79). At 5 years after diagnosis of breast cancer, secondary cancer occurred in 48 patients (44.4%), with 50.0% of the endometrial, 56.3% of the stomach, and 37.8% of the thyroid cancer cases being diagnosed after 5 years. Median survival after diagnosis of the second cancer was 123.9±11.2 months. The prognosis was mainly influenced by the anatomic site.
Conclusion
The incidence of endometrial, stomach, and thyroid cancer increased significantly after treatment with primary breast cancer, and survival was dependent on early detection and the type of second primary cancer. A prolonged follow-up examination for metachronous double primary cancer is needed to provide early detection and improve survival time in patients with breast cancer.

Citations

Citations to this article as recorded by  
  • Deciphering the Patterns of Dual Primary Cases Registered at the Hospital-Based Cancer Registry: First Experience from Rural Cancer Center in North India
    Sankalp Sancheti, Alok Kumar Goel, Anshul Singla, Kuldeep Singh Chauhan, Kiran Arora, Debashish Chaudhary, Tapas Dora, Shweta Tahlan, Prithviraj Kadam, Prachi Joshi, Akash Sali, Rahatdeep Singh Brar, Atul Budukh, Ashish Gulia, Jigeeshu Vasishtha Divatia,
    Journal of Laboratory Physicians.2023; 15(04): 524.     CrossRef
  • Multiple synchronous primary malignant neoplasms: A case report and literature review
    Linlin Hao, Lihui Zhang, Chuanjie Xu, Min Jiang, Geyi Zhu, Jie Guo
    Oncology Letters.2023;[Epub]     CrossRef
  • Association between Thyroid Cancer and Breast Cancer: Two Longitudinal Follow-Up Studies Using a National Health Screening Cohort
    Young Ju Jin, Mi Jung Kwon, Ji Hee Kim, Joo-Hee Kim, Hyo Geun Choi
    Journal of Personalized Medicine.2022; 12(2): 133.     CrossRef
  • Simultaneous gastric cancer and breast cancer metastases to the stomach with lymph node collision tumor: a case report
    Takeshi Okamoto, Hidekazu Suzuki, Katsuyuki Fukuda
    BMC Gastroenterology.2021;[Epub]     CrossRef
  • Pioneering BRCA1/2 Point-Of-Care Testing for Integration of Germline and Tumor Genetics in Breast Cancer Risk Management: A Vision for the Future of Translational Pharmacogenomics
    Lwando Mampunye, Nerina C. van der Merwe, Kathleen A. Grant, Armand V. Peeters, Rispah Torrorey-Sawe, David J. French, Kelebogile E. Moremi, Martin Kidd, Petrus C. van Eeden, Fredrieka M. Pienaar, Maritha J. Kotze
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • The Pattern of Second Primary Tumours in Postmenopausal Women with Prior Breast Cancer in Western Romania: A Retrospective, Single-Institution Study
    Cristina Marinela Oprean, Larisa Maria Badau, Robert-Alexandru Han, Teodora Hoinoiu, Gabriel-Mugur Dragomir, Daciana Grujic, Tiberiu Dragomir, Alis Dema
    Diagnostics.2021; 11(11): 1957.     CrossRef
  • High Incidence and Prevalence of Papillary Thyroid Cancer in Breast Cancer Patients
    Jung Ho Park, Sanghwa Kim, Lee Su Kim
    Journal of Endocrine Surgery.2020; 20(4): 88.     CrossRef
  • Gastric Complications after Adjuvant Radiotherapy for Breast Cancer
    Won Kyung Cho, Doo Ho Choi, Won Park, Haeyoung Kim, Seonwoo Kim, Myung-Hee Shin, Hyejung Cha
    Journal of Breast Cancer.2019; 22(3): 464.     CrossRef
  • Clinical Characteristics and Prognosis Associated with Multiple Primary Cancers in Breast Cancer Patients
    Bong Kyun Kim, Se Jeong Oh, Jeong-Yoon Song, Han-Byoel Lee, Min Ho Park, Yongsik Jung, Woo-Chan Park, Jina Lee, Woo Young Sun
    Journal of Breast Cancer.2018; 21(1): 62.     CrossRef
  • Detection of the early phase of esophageal cancer progression into lamina propria mucosae by the serum p53 antibody
    Fumi Saito, Hideaki Shimada, Hideaki Ogata, Takafumi Otsuka, Tetsuo Nemoto, Kazutoshi Shibuya, Hironori Kaneko
    Esophagus.2017; 14(4): 366.     CrossRef
  • Metachronous double primary cancer of epithelial and mesenchymal origins
    Hongzeng Wu, Ze Li, Helin Feng, Jinming Zhang
    Medicine.2017; 96(49): e9036.     CrossRef
  • Development of second primary cancer in Korean breast cancer survivors
    Hong Kyu Jung, Suyeon Park, Nam Won Kim, Jong Eun Lee, Zisun Kim, Sun Wook Han, Sung Mo Hur, Sung Young Kim, Cheol Wan Lim, Min Hyuk Lee, Jihyoun Lee
    Annals of Surgical Treatment and Research.2017; 93(6): 287.     CrossRef
  • Multiple primary tumours: challenges and approaches, a review
    Alexia Vogt, Sabine Schmid, Karl Heinimann, Harald Frick, Christian Herrmann, Thomas Cerny, Aurelius Omlin
    ESMO Open.2017; 2(2): e000172.     CrossRef
  • Characteristics and survival of patients with metachronous or synchronous double primary malignancies: breast and thyroid cancer
    Li Zhang, Yansheng Wu, Fangfang Liu, Li Fu, Zhongsheng Tong
    Oncotarget.2016; 7(32): 52450.     CrossRef
  • Radiotherapy did not increase thyroid cancer risk among women with breast cancer: A nationwide population‐based cohort study
    Li‐Min Sun, Cheng‐Li Lin, Ji‐An Liang, Wen‐Sheng Huang, Chia‐Hung Kao
    International Journal of Cancer.2015; 137(12): 2896.     CrossRef
  • A Possible Association Between Thyroid Cancer and Breast Cancer
    Jee Hyun An, Yul Hwangbo, Hwa Young Ahn, Bhumsuk Keam, Kyu Eun Lee, Wonshik Han, Do Joon Park, In Ae Park, Dong-Young Noh, Yeo-Kyu Youn, Bo Youn Cho, Seock-Ah Im, Young Joo Park
    Thyroid.2015; 25(12): 1330.     CrossRef
  • 14,348 View
  • 120 Download
  • 24 Web of Science
  • 16 Crossref
Close layer
Clinical Outcome of Rituximab-Based Therapy (RCHOP) in Diffuse Large B-Cell Lymphoma Patients with Bone Marrow Involvement
Byung Woog Kang, Joon Ho Moon, Yee Soo Chae, Soo Jung Lee, Jong Gwang Kim, Yeo-Kyeoung Kim, Je-Jung Lee, Deok-Hwan Yang, Hyeoung-Joon Kim, Jin Young Kim, Young Rok Do, Keon Uk Park, Hong Suk Song, Ki Young Kwon, Min Kyung Kim, Kyung Hee Lee, Myung Soo Hyun, Hun Mo Ryoo, Sung Hwa Bae, Hwak Kim, Sang Kyun Sohn
Cancer Res Treat. 2013;45(2):112-117.   Published online June 30, 2013
DOI: https://doi.org/10.4143/crt.2013.45.2.112
AbstractAbstract PDFPubReaderePub
PURPOSE
We investigated the clinical outcome of bone marrow (BM) involvement in patients with diffuse large B-cell lymphoma (DLBCL) who received rituximab-based therapy.
MATERIALS AND METHODS
A total of 567 consecutive patients with newly diagnosed DLBCL treated with rituximab-CHOP (RCHOP) between November 2001 and March 2010 were included in the current study. All of the patients underwent a BM study at the initial staging and the clinical characteristics and prognosis of these patients with or without BM involvement were analyzed retrospectively.
RESULTS
The total cohort included 567 patients. The overall incidence of BM involvement was 8.5%. With a median follow-up duration of 33.2 months (range, 0.1 to 80.7 months) for patients who were alive at the last follow-up, the five-year overall survival (OS) and event-free survival (EFS) rate in patients without BM involvement (76.3% and 67.5%, p<0.001) was statistically higher than that in patients with BM involvement (44.3% and 40.1%, p<0.001). In multivariate analysis, among total patients, BM involvement showed a significant association with OS and EFS. In univariate and multivariate analyses, even among stage IV patients, a significant association with worse EFS was observed in the BM involvement group.
CONCLUSION
BM involvement at diagnosis affected the survival of patients with DLBCL who received RCHOP. Although use of RCHOP can result in significant improvement of the therapeutic effect of DLBCL, BM involvement is still a negative prognostic factor of DLBCL patients in the era of rituximab.

Citations

Citations to this article as recorded by  
  • Combination of Bone Marrow Biopsy and Flow Cytometric Analysis: The Prognostically Relevant Central Approach for Detecting Bone Marrow Invasion in Diffuse Large B-Cell Lymphoma
    Haruya Okamoto, Nobuhiko Uoshima, Ayako Muramatsu, Reiko Isa, Takahiro Fujino, Yayoi Matsumura-Kimoto, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Tsutomu Kobayashi, Eri Kawata, Hitoji Uchiyama, Junya Kuroda
    Diagnostics.2021; 11(9): 1724.     CrossRef
  • Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility
    Jeffrey W. Craig, Michael J. Mina, Jennifer L. Crombie, Ann S. LaCasce, David M. Weinstock, Geraldine S. Pinkus, Olga Pozdnyakova, Francesco Bertolini
    PLOS ONE.2018; 13(7): e0199708.     CrossRef
  • HIV-infection impact on clinical–biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era
    Maria Joao Baptista, Olga Garcia, Mireia Morgades, Eva Gonzalez-Barca, Pilar Miralles, Armando Lopez-Guillermo, Eugenia Abella, Miriam Moreno, Juan-Manuel Sancho, Evarist Feliu, Josep-Maria Ribera, Jose-Tomas Navarro
    AIDS.2015; 29(7): 811.     CrossRef
  • Non-Hodgkin Lymphomas: Impact of Rituximab on Overall Survival of Patients with Diffuse Large B-Cell and Follicular Lymphoma
    José Carlos Jaime-Pérez, Carmen Magdalena Gamboa-Alonso, Alberto Vázquez-Mellado de Larracoechea, Marisol Rodríguez-Martínez, César Homero Gutiérrez-Aguirre, Luis Javier Marfil-Rivera, David Gómez-Almaguer
    Archives of Medical Research.2015; 46(6): 454.     CrossRef
  • 24,960 View
  • 63 Download
  • 4 Crossref
Close layer
Metachronous Double Primary Cancer after Diagnosis of Gastric Cancer
Jin Young Kim, Won Young Jang, Mi Hwa Heo, Kang Kuk Lee, Young Rok Do, Keon Uk Park, Hong Suk Song, Yoon Nyun Kim
Cancer Res Treat. 2012;44(3):173-178.   Published online September 30, 2012
DOI: https://doi.org/10.4143/crt.2012.44.3.173
AbstractAbstract PDFPubReaderePub
PURPOSE
The pattern of double primary cancers after treatment for gastric cancer is important for a patient's survival.
MATERIALS AND METHODS
We analyzed the clinicopathologic data of 214 gastric cancer patients from October 1996 to November 2007 with regard to metachronous second primary cancers.
RESULTS
Out of 5,778 patients with gastric cancer, metachronous second primary cancers occurred in 214 patients. The median age was 61.8 years, the number of male and female patients was 140 (65.4%), 74 (34.6%), respectively. The median time to the occurrence of second cancers after diagnosis of the first was 39.2 months (standard deviation, 31.2 months). The most common cancer was colorectal cancer, which occurred in 44 patients (20.6%), and lung cancer in 33 patients (15.4%), hepatocellular carcinoma in 26 patients (12.1%), ovarian cancer in 15 patients (7.0%), cervical cancer in 12 patients (7.0%), breast cancer in 11 patients (5.1%), and esophageal cancer in 11 patients (5.1%). The observed/expected (O/E) ratio showed a significant increase in colorectal (1.25), male biliary (1.60), ovarian (8.72), and cervical cancer (3.33) with primary gastric cancer. After five years from diagnosis of gastric cancer, secondary cancer occurred in 50 patients (23.4%), and breast cancer, prostate cancer, laryngeal cancer, lung cancer, and hepatocellular carcinoma were the most frequent.
CONCLUSION
The O/E ratio showed a significant increase in colorectal, male biliary, ovarian, and cervical cancer with primary gastric cancer, and second primary cancer as the main cause of death for these patients. A follow-up examination for metachronous double primary cancer is needed in order to improve the survival time in patients with gastric cancer.

Citations

Citations to this article as recorded by  
  • Gastric Metastasis Mimicking Early Gastric Cancer from Invasive Ductal Carcinoma of the Breast: Case Report and Literature Review
    Kwon Cheol Yoo, Dae Hoon Kim, Sungmin Park, HyoYung Yun, Dong Hee Ryu, Jisun Lee, Seung-Myoung Son
    Medicina.2024; 60(6): 980.     CrossRef
  • Synchronous gastric and ovarian cancer successfully treated with FOLFOX therapy: a case report and review of the literature
    Makiko So, Aya Shimoji, Yoko Iemura, Ai Suizu, Shuichiro Iwami, Masahito Hoki, Shinsuke Shibuya
    International Cancer Conference Journal.2024; 13(4): 427.     CrossRef
  • Incidence and pattern of second primary cancer in patients diagnosed with primary cancer
    Jong Sung, Ae Ahn, Ho Park, Kyu Jang, Woo Moon, Ju-Hyung Lee, Kyoung Kim, Myoung Chung
    Oncology Letters.2024;[Epub]     CrossRef
  • The risk and distribution of second primary cancers according to subsite of primary stomach cancer: a retrospective cohort population-based study
    Ali Hemade, Souheil Hallit
    Annals of Medicine & Surgery.2024; 86(12): 6944.     CrossRef
  • Features of synchronous and metachronous dual primary gastric and colorectal cancer
    Yi-Jia Lin, Hua-Xian Chen, Feng-Xiang Zhang, Xian-Sheng Hu, Hai-Juan Huang, Jian-Hua Lu, Ye-Zi Cheng, Jun-Sheng Peng, Lei Lian
    World Journal of Gastrointestinal Oncology.2023; 15(11): 1864.     CrossRef
  • Secondary Primary Cancer after Primary Gastric Cancer: Literature Review and Big Data Analysis Using the Health Insurance Review and Assessment Service (HIRA) Database of Republic of Korea
    Jeong Ho Song, Yeonkyoung Lee, Jaesung Heo, Sang-Yong Son, Hoon Hur, Sang-Uk Han
    Cancers.2022; 14(24): 6165.     CrossRef
  • Simultaneous gastric cancer and breast cancer metastases to the stomach with lymph node collision tumor: a case report
    Takeshi Okamoto, Hidekazu Suzuki, Katsuyuki Fukuda
    BMC Gastroenterology.2021;[Epub]     CrossRef
  • The contribution of second primary cancers to the mortality of patients with a gastric first primary cancer
    Samantha Morais, Luís Antunes, Maria J. Bento, Nuno Lunet
    European Journal of Gastroenterology & Hepatology.2019; 31(4): 471.     CrossRef
  • Second Primary Cancer after Treating Gastrointestinal Cancer
    Jeong Youp Park
    The Korean Journal of Gastroenterology.2019; 74(4): 193.     CrossRef
  • Gastric cancer and intrahepatic cholangiocarcinoma
    Alex Emmanuel Elobu, Ashok Thorat, Vianney Kweyamba, Rakesh Rai
    Formosan Journal of Surgery.2019; 52(3): 107.     CrossRef
  • Occurrence of metachronous multiple primary cancers occurred in different parts of the stomach with 2 pathologic features
    Yan Song, Ningning Zhao, Kui Jiang, Zhongqing Zheng, Bangmao Wang, Dalu Kong, Shu Li
    Medicine.2018; 97(20): e10803.     CrossRef
  • Surgical Strategy and Outcome in Patients Undergoing Pancreaticoduodenectomy After Gastric Resection: A Three‐Center Experience with 39 Patients
    Dooin Lee, Jae Hoon Lee, Dongho Choi, Chang Moo Kang, Jae Uk Chong, Song‐Chul Kim, Kyeong Geun Lee
    World Journal of Surgery.2017; 41(2): 552.     CrossRef
  • Risk of second primary cancers among patients with a first primary gastric cancer: A population-based study in North Portugal
    Samantha Morais, Luís Antunes, Maria José Bento, Nuno Lunet
    Cancer Epidemiology.2017; 50: 85.     CrossRef
  • Incidence of Gastric Cancer in Patients with Laryngeal Cancer
    Ji-Hyun Seo, Hyun-Jin Kim, Jung Je Park, Ok-Jae Lee, Jin Pyeong Kim, Seong-Ki Ahn, Jeong Seok Hwa, Jong Sil Lee, Hee-Shang Youn
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2017; 17(4): 190.     CrossRef
  • Second primary malignancy risk among patients with gastric cancer: a nationwide population-based study in Taiwan
    San-Chi Chen, Chia-Jen Liu, Yu-Wen Hu, Chiu-Mei Yeh, Li-Yu Hu, Yen-Po Wang, Yi-Ping Hung, Cheng-Hwai Tzeng, Tzeon-Jye Chiou, Tzeng-Ji Chen, Chung-Jen Teng
    Gastric Cancer.2016; 19(2): 490.     CrossRef
  • Secondary Primary Malignancy Risk in Patients With Ovarian Cancer in Taiwan
    Yi-Ping Hung, Chia-Jen Liu, Yu-Wen Hu, Min-Huang Chen, Chun-Pin Li, Chiu-Mei Yeh, Tzeon-Jye Chiou, Tzeng-Ji Chen, Muh-Hwa Yang, Yee Chao
    Medicine.2015; 94(38): e1626.     CrossRef
  • Role of Ki‐67 Proliferation Index in the Assessment of Patients with Neuroendocrine Neoplasias Regarding the Stage of Disease
    H. C. Miller, P. Drymousis, R. Flora, R. Goldin, D. Spalding, A. Frilling
    World Journal of Surgery.2014; 38(6): 1353.     CrossRef
  • Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer
    Chan Kim, Hong Jae Chon, Beodeul Kang, Kiyeol Kim, Hei-Cheul Jeung, Hyun Cheol Chung, Sung Hoon Noh, Sun Young Rha
    BMC Cancer.2013;[Epub]     CrossRef
  • 11,724 View
  • 89 Download
  • 18 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP